Phase IIb study on ANAB's ANB032 for atopic dermatitis fails to meet goals. The company decides to discontinue any further investment in the candidate.

AnaptysBio has reported that the ARISE-AD trial of its investigational B and T lymphocyte attenuator (BTLA) agonist, ANB032, ...

AnaptysBio, Inc. (NASDAQ:ANAB) announced that investigational ANB032, a BTLA agonist, did not meet the primary and secondary ...

In a report released today, Emily Bodnar from H.C. Wainwright downgraded AnaptysBio (ANAB – Research Report) to a Hold, with a price target of ...

San Diego, USA-based biotech AnaptysBio today announced that investigational ANB032, a BTLA agonist, did not meet the primary ...

AnaptysBio is dropping its atopic dermatitis (AD) drug candidate after the compound failed to reduce eczema area and itch ...

AnaptysBio (ANAB) announced that investigational ANB032, a BTLA agonist, did not meet the primary and secondary endpoints in any of the doses ...

Return on Equity (ROE): AnaptysBio's ROE is below industry averages, indicating potential challenges in efficiently utilizing ...

1 Day ANAB -0.51% DJIA -0.31% Russell 2K 0.08% Health Care/Life Sciences -0.22% ...

AnaptysBio, Inc. (ANAB) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the ...

AnaptysBio has been able to use its technology ... and strong activity in reducing pathogenic T-cells. ANB032, their BTLA agonist, is also in Phase 2b trials for atopic dermatitis.